Novartis AG (0QLR.IL)
| Previous Close | 84.06 |
| Open | 84.15 |
| Bid | 82.12 x N/A |
| Ask | 86.33 x N/A |
| Day's Range | 83.65 - 84.74 |
| 52 Week Range | 73.79 - 94.77 |
| Volume | |
| Avg. Volume | 964,190 |
| Market Cap | 193.116B |
| Beta (5Y Monthly) | 0.49 |
| PE Ratio (TTM) | 26.24 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.20 (3.78%) |
| Ex-Dividend Date | Mar 09, 2023 |
| 1y Target Est | N/A |
- GlobeNewswire
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS)1,2 iDFS benefit remains consistent across key patient subgroups; among patients with stage II and stage III tumors, Kisqali lowered risk by 30% and 24.5%, respectively1,2 Latest analysis continues to show a well-tolerated safety profile in line with pre
- PR Newswire
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta® (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)1. Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH]). In clinical trial
- GlobeNewswire
Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day
Ad hoc announcement pursuant to Art. 53 LR ‘Pure-play’ innovative medicines strategy focused on four therapeutic areas and five technology platforms, which offer potential for consistent growth Mid-term sales guidance upgrade to 5% CAGR (2022-27), with core operating income margin of ~40%+ by 2027, driven by continued strong momentum of key growth drivers Confidence to grow mid-single digit longer-term based on the foundational strength of de-risked existing brands and pipeline assets Focused st
